Item 2.01
Completion of Acquisition or Disposition of Assets
On September 12, 2018, Cambrex Corporation (the Company) completed the previously announced acquisition of all of the outstanding shares of Halo Pharmaceutical, Inc., a Delaware corporation (Halo US), 8121117 Canada Inc., a corporation organized under the laws of Canada (Halo 812), Halo Pharmaceutical Canada Inc., a corporation organized under the laws of Canada (Halo Canada and together with Halo US, Halo 812 and their respective Subsidiaries, the Acquired Companies or Halo) pursuant to the Purchase and Sale Agreement, dated July 20, 2018, between the Company, the Acquired Companies, the holders of all the outstanding shares of the Acquired Companies (collectively, the Sellers), SK Capital Partners, L.P., a Delaware limited partnership, as representative of the Sellers and SK Angel Holdings, L.P., a Cayman Islands exempted limited partnership, as guarantor of the Sellers, a copy of which was previously filed as Exhibit 2.1 to the Companys quarterly report on Form 10-Q for the period ended June 30, 2018. An aggregate purchase price of approximately U.S. $425 million in cash was paid as consideration. Halo is a leading dosage form Contract Development and Manufacturing Organization located in Whippany, New Jersey and Mirabel, Quebec, Canada.
